Livzon Pharmaceutical Group Inc
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more
Market Cap & Net Worth: Livzon Pharmaceutical Group Inc (LVZPF)
Livzon Pharmaceutical Group Inc (PINK:LVZPF) has a market capitalization of $1.03 Billion ($1.03 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #5665 globally and #3302 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Livzon Pharmaceutical Group Inc's stock price $3.43 by its total outstanding shares 299807117 (299.81 Million).
Livzon Pharmaceutical Group Inc Market Cap History: 2018 to 2025
Livzon Pharmaceutical Group Inc's market capitalization history from 2018 to 2025. Data shows growth from $21.41 Million to $1.03 Billion (68.97% CAGR).
Livzon Pharmaceutical Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Livzon Pharmaceutical Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
Livzon Pharmaceutical Group Inc's market cap is 0.08 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.48x
Livzon Pharmaceutical Group Inc's market cap is 0.48 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $21.41 Million | $8.86 Billion | $1.08 Billion | 0.00x | 0.02x |
| 2019 | $29.62 Million | $9.38 Billion | $1.30 Billion | 0.00x | 0.02x |
| 2020 | $39.96 Million | $10.52 Billion | $1.71 Billion | 0.00x | 0.02x |
| 2021 | $67.64 Million | $12.06 Billion | $1.78 Billion | 0.01x | 0.04x |
| 2022 | $96.42 Million | $12.63 Billion | $1.91 Billion | 0.01x | 0.05x |
| 2023 | $289.40 Million | $12.43 Billion | $1.95 Billion | 0.02x | 0.15x |
| 2024 | $983.37 Million | $11.81 Billion | $2.06 Billion | 0.08x | 0.48x |
Competitor Companies of LVZPF by Market Capitalization
Companies near Livzon Pharmaceutical Group Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Livzon Pharmaceutical Group Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Livzon Pharmaceutical Group Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Livzon Pharmaceutical Group Inc's market cap moved from $21.41 Million to $ 1.03 Billion, with a yearly change of 68.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.03 Billion | +4.57% |
| 2024 | $983.37 Million | +239.79% |
| 2023 | $289.40 Million | +200.16% |
| 2022 | $96.42 Million | +42.55% |
| 2021 | $67.64 Million | +69.24% |
| 2020 | $39.96 Million | +34.92% |
| 2019 | $29.62 Million | +38.38% |
| 2018 | $21.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Livzon Pharmaceutical Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.